Journal of Clinical Densitometry
Volume 11, Issue 3 , Pages 417-423 , July 2008

Rapid Suppression of Bone Resorption Marker Levels With Ibandronate Therapy in a Bisphosphonate-Naïve Population

  • A.I. Sebba

      Affiliations

    • University of South Florida, Tampa, FL, USA
    • Corresponding Author InformationAddress correspondence to: Anthony I. Sebba, MD, University of South Florida, 36338 US Highway 19N, Tampa, FL 33620.
    • ,
  • S. Broy

      Affiliations

    • Illinois Bone and Joint Institute, Morton Grove, IL, USA
    • ,
  • J.D. Kohles

      Affiliations

    • Roche, Nutley, NJ, USA
    • ,
  • P. Weissman

      Affiliations

    • University of Miami, Miami, FL, USA

Received 31 October 2007 ,Revised 22 January 2008 ,Accepted 25 February 2008.

References 

  1. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11:337–349
  2. Miller PD, Hochberg MC, Wehren LE, et al. How useful are measures of BMD and bone turnover?. Curr Med Res Opin. 2005;21:545–554
  3. Melton LJ, Khosla S, Atkinson EJ, et al. Relationship of bone turnover to bone density and fractures. J Bone Miner Res. 1997;12:1083–1091
  4. Harris ST, Gertz BJ, Genant HK, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab. 1993;76:1399–1406
  5. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med. 2006;119:S25–S31
  6. Cremers S, Garnero P. Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs. 2006;66:2031–2058
  7. Greenspan SL, Parker RA, Ferguson L, et al. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998;13:1431–1438
  8. Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab. 2005;90:2762–2767
  9. Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab. 2000;85:3537–3540
  10. Kim SW, Park do J, Park KS, et al. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J. 2005;52:667–674
  11. Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int. 2000;11(Suppl 6):S2–S17
  12. Garnero P. Markers of bone turnover for the prediction of fracture risk. Osteoporos Int. 2000;11(Suppl 6):S55–S65
  13. Garnero P, Delmas PD. Biochemical markers of bone turnover. Applications for osteoporosis. Endocrinol Metab Clin North Am. 1998;27:303–323
  14. Leeming DJ, Alexandersen P, Karsdal MA, et al. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol. 2006;62:781–792
  15. Friedman AW. Important determinants of bone strength: beyond bone mineral density. J Clin Rheumatol. 2006;12:70–77
  16. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996;11:1531–1538
  17. Miller PD. Monitoring osteoporosis therapies. Curr Osteoporos Rep. 2007;5:38–43
  18. Delmas PD, Vrijens B, Eastell R, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2007;92:1296–1304
  19. Rizzoli R. Long-term outcome of weekly bisphosphonates. Clin Orthop Relat Res. 2006;443:61–65
  20. Boniva (ibandronate sodium). [US prescribing information] Nutley, NJ: Roche Laboratories, Inc; 2005;
  21. Delmas PD, Recker RR, Chesnut CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004;15:792–798
  22. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20:1315–1322
  23. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis. 2006;65:654–661
  24. Kung A, Rovayo R, Guesens P, et al. Results of a three-month randomized trial to examine week-by-week effects of monthly ibandronate on biochemical markers of bone resorption. Osteoporos Int. 2006;17:S94–S95
  25. Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem. 2001;47:694–702
  26. Chiu KM, Ju J, Mayes D, et al. Changes in bone resorption during the menstrual cycle. J Bone Miner Res. 1999;14:609–615
  27. Gorai I, Chaki O, Nakayama M, Minaguchi H. Urinary biochemical markers for bone resorption during the menstrual cycle. Calcif Tissue Int. 1995;57:100–104
  28. Gorai I, Taguchi Y, Chaki O, et al. Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle. J Clin Endocrinol Metab. 1998;83:326–332
  29. Nielsen HK, Brixen K, Bouillon R, Mosekilde L. Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J Clin Endocrinol Metab. 1990;70:1431–1437
  30. Derman RJ, Kohles JD, Gass ML. 2007 Physiological pattern of sCTX in relation to the menstrual cycle of healthy women. Paper presented at: International Society for Clinical Densitometry; Tampa, FL; March 14–17, 2007.

PII: S1094-6950(08)00033-4

doi: 10.1016/j.jocd.2008.02.004

Journal of Clinical Densitometry
Volume 11, Issue 3 , Pages 417-423 , July 2008

Article Tools

* Image Usage & Resolution